Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
Completed · Phase 2 · NCT03996291
Conditions: Relapsing Multiple Sclerosis
At a glance
- Research payments reported, 2025
- $102,579
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 125
About the trial
- Sponsor
- Sanofi
- Tested
- Tolebrutinib (drug)
- Dates
- Started 2019-09-23; completion 2024-11-26
- Results posted
- Yes
Primary Objective: To determine the long-term safety and tolerability of SAR442168 in RMS participants Secondary Objective: To evaluate efficacy of SAR442168 on disease activity, assessed by clinical and imaging methods
From ClinicalTrials.gov, last updated 2025-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $102,579 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christopher C. Laganke, MD Neurology · Cullman, AL
- Wm D. Honeycutt, M.D. Specialist · Maitland, FL
- Derrick S. Robertson, M.D. Neurology · Tampa, FL
- Daniel R. Wynn, M.D. Neurology · Northbrook, IL
- Lawrence P. Goldstick, MD Neurology · Dayton, OH
- Sibyl Wray, MD Neurology · Knoxville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Neurology Associates, PA $77,492
- Consultants in Neurology, Ltd $11,370
- University of Cincinnati Physicians Company Llc $5,498
- Sibyl Wray MD Neurology PC $3,069
- $2,500
- University of South Florida $1,650
- 0000203566 North Central Neurology Assocs PC $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.